Modulation of angiogenesis for cancer prevention: Strategies based on antioxidants and copper deficiency

Current Pharmaceutical Design

Volumn 13, Issue 35, 2007, Pages 3584-3590

  Khan, Gazala N ^a   Merajver, Sofia D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Anti oxidants; Cancer prevention; Copper chelation; In vitro studies; In vivo studies; Nutraceuticals; Tetrathiomolybdate

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BEVACIZUMAB; CAROTENOID; COPPER; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; FINASTERIDE; FLUOROURACIL; FOLINIC ACID; FREE RADICAL; FUMAGILLOL CHLOROACETYLCARBAMATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; MOLYBDIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NUTRACEUTICAL; OXALIPLATIN; PLACEBO; POLYPHENOL; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; SUNITINIB; TETRATHIMOLYBDATE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COLON CANCER; COPPER DEFICIENCY; DRUG DOSE REDUCTION; FEASIBILITY STUDY; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LONG TERM CARE; MICROENVIRONMENT; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION; WILSON DISEASE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BREAST NEOPLASMS; CAROTENOIDS; CELL TRANSFORMATION, NEOPLASTIC; CHELATING AGENTS; COPPER; DIETARY SUPPLEMENTS; FEMALE; FLAVONOIDS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MOLYBDENUM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHENOLS; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 36948999179     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782794202     Document Type: Review

References (75)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86.
2. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible of angiogenesis. J Exp Med 1971; 133: 275-88.
3. Folkman J. Incipient angiogenesis. J Natl Cancer Inst 2000; 92: 94-5.
4. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21: 525-30.
5. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251-6.
6. Decensi A, Costa A. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur J Cancer 2000; 36: 694-09.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
8. Papetti M. Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-70.
9. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
10. Hlatky L. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883-93.
11. Rodríguez-Manzaneque, Lane TF, María AO, Hynes RO, Lawler JM, Iruela-Arispe L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98: 12485-90.
12. Kerbel R. Clinical translation of angiogenesis inhibitors. Nat Rev 2002; 727-39.
13. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11: 617-24.
14. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5:1359-64.
15. Stinchcombe TE, Socinski MA. Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 2007; 26: 3691-8.
16. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Journal of Clinical Oncology; ASCO Annual Meeting Proceedings 2006; 3510.
17. Mcmeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 105: 508-16.
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
19. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 7889-96.
20. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24: 3555-61.
21. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7: 545-53.
22. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
23. Israel A. A role for phosphorylation and degradation in the control of NF-kappa B activity. Trends Genet 1995; 6: 203-5.
24. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42.
25. Chilov D, Kukk E, Taira S, Jeltsch K Kaukonen J, Palotie A, et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997; 272: 25176-83.
26. Levine L, Lucci JA 3rd, Pazdrak B, Cheng JZ, Guo YS, Townsend CM Jr, et al. Bombesin stimulates nuclear factor κB activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003; 63: 3495-502.
27. Yu HG, Zhong X, Yang YN, Luo HS, Yu JP, Meier JJ, et al. Increased expression of nuclear factor-kappaB/RelA is correlated with tumor angiogenesis in human colorectal cancer. Int J Colorectal Dis 2004; 19: 18-22.
28. Strauss SJ, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D, et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007; 67: 2783-90.
29. Agou F, Courtois G, Chiaravalli J, Baleux F, Coic YM, Traincard F, et al. Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. J Biol Chem 2004; 279: 54248-57.
30. 1 and copper in angiogenesis. J Natl Cancer Inst 1982; 69: 475-82.
31. Brem S. Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control 1999; 6: 436-58.
32. Brewer GJ. Novel therapeutic approaches to the treatment of Wilson's disease. Expert Opin Pharmacother 2006; 7: 317-24.
33. Goodman VL, Brewer GJ, Merajver SD. Control of copper status for cancer therapy. Curr Cancer Drug Targets 2005; 5: 543-9.
34. Cox C, Teknos TN, Barrios N, Brewer GJ, Rick RD, Merajver SD. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001; 111: 696-701.
35. Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 2007; 6: 1039-45.
36. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002; 62: 4854-9.
37. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFκB signaling cascade. Mol Cancer Res 2003; 1: 701-6.
38. Brewer GJ, Rick RD, Grover DK, LeClaire V, Tseng M, Wicha M. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000; 6: 1-10.
39. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003; 9: 1666-72.
40. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996; 93: 2002-7.
41. Albini A, Tosetti F, Benelli R, Noona DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005; 65: 10637-41.
42. Pfeffer U, Ferrari N, DellEva R, Indraccolo S, Monnini M, Noonan DM, et al. Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: microarray gene expression analyses. Mutat Res 2005; 591: 198-11.
43. Maulik N. Redox signaling of angiogenesis. Antioxid Redox Signal 2002; 4: 805-15.
44. Maulik N, Das DK. Redox signaling in vascular angiogenesis. Free Radic Biol Med 2002; 33: 1047-60.
45. Djuric Z, Klitschevsky D, Modulation of oxidative DNA damage levels by dietary fat and calories. Mutat Res 1993; 295: 181-90
46. Djuric Z, Heilbrun LK, Simon MS, Smith D, Luongo DA, LoRusso PM, et al. Levels of 5-hydroxymethyl-2′-deoxyuridine in DNA from blood as a marker of breast cancer. Cancer 1996; 77: 691-6.
47. Djuric Z, Depper JB, Uhley B, Smith D, Lahabidi S, Martino S, et al. Oxidative DNA damage levels in blood from women at high risk for breast cancer are associated with dietary intakes of meats, vegetables, and fruits. J Am Diet Assoc 1998; 98: 524-8.
48. Dragsted LO, Strube M, Larsen JC. Cancer-protective factors in fruits and vegetables: biochemical and biological background. Pharmacol Toxicol 1993; 72: 116-35.
49. Polytarchou C, Papadimitriou E. Antioxidants inhibit human endothelial cell functions through down-regulation of endothelial nitric oxide synthase activity. Eur J Pharmacol 2005; 510: 31-8.
50. Polytarchou C, Papadimitriou E. Antioxidants inhibit angiogenesis in vivo through down-regulation of nitric oxide synthase expression and activity. Free Radic Res 2004; 38: 501-8.
51. Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 2001; 21: 381-06.
52. Chambon P. The molecular and genetic dissection of the retinoid signaling pathway. Recent Prog Horm Res 1995; 50: 317-32
53. Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 1987; 71: 3911-5.
54. Watson RR, Prabhlala RH, Plezia PM, Alberts DS. Effect of betacarotene on lymphocyte subpopulations in elderly humans: evidence for a dose-response relationship. Am J Clin Nut 1991; 53: 90-4.
55. Zhang LX, Cooney RV, Bertram JS. Carotenoids up-regulate connexin43 gene expression independent of their provitamin A or antioxidant properties. Cancer Res 1992; 52: 5707-12.
56. McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp Biol Med 2007; 232: 523-31.
57. Alpha-Tocopherol Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
58. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
59. Lippman SM, Spitz MR. Lung cancer chemoprevention: An integrated approach. J Clin Oncol 2001; 19: 74-82.
60. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276: 1957-63.
61. Yoshizawa K, Willett WC, Morris SJ, Slate EH, Chalker DK, Chow J, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998; 90: 1219-24.
62. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90: 440-6.
63. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, et al. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 2001; 12: 627-33.
64. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al. SELECT: The next prostate cancer prevention trial - Selenium and Vitamin E Cancer Prevention Trial. J Urol 2001; 166: 1311-5.
65. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992; 18: 1-29.
66. Middleton Jr. E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52: 673-51.
67. Waladkhani A. R., Clemens M. R. Effect of dietary phytochemicals on cancer development. Bioorg Med Chem Lett 1998; 1: 747-53.
68. Narayanan BA, Ree GG. IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid. Anticancer Res 2001; 21: 359-64.
69. Narayanan BA, Geoffroy O, Willingham MC, Ree GG, Nixon DW. p53/p21(WAF1/ CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett 1999; 136: 215-21.
70. Ignaro LJ, Byrns RE, Sumi D, Napoli C. Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide. Nitric Oxide 2006; 15: 93-102.
71. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram. NP, Shishodia S, Takada Y. Role of resveratrol in the prevention and therapy of cancer: pre-clinical and clinical studies. Anticancer Res 2004; 24: 2783-840.
72. Geschcr A. Polyphenolic phytochemicals vs. Nonsteroidal antiin-flammatory drugs: which are better cancer chemopreventive agents? J Chemother 2004; 16: 3-6.
73. Fry FH, Jacob C. Sensor/effector drug design with potential relevance to cancer. Curr Pharm Des 2006; 12(34): 4479-99.
74. Ruano-Ravina A, Figueiras A, Freire-Garabal K Barros-Dios JM. Antioxidant vitamins and risk of lung cancer. Curr Pharm Des 2006; 12(5): 599-613.
75. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007; 13(1): 3-16.